Immunovant
IMVT
24 hedge funds and large institutions have $176M invested in Immunovant in 2019 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 11 closing their positions.
382% more capital invested
Capital invested by funds: $36.6M → $176M (+$140M)
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
71% more funds holding
Funds holding: 14 → 24 (+10)
5.02% less ownership
Funds ownership: 25.6% → 20.58% (-5%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$49.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11.4M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$11.2M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$8.96M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$8.81M |
| 2 |
GL
Governors Lane
New York
|
-$8.21M |
| 3 |
DKCM
Davidson Kempner Capital Management
New York
|
-$5.13M |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$3.94M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$3.01M |
IMVT Hedge Fund Activity: Q4 2019 in Review
24 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2019, worth a combined $176M — up 382% from $36.6M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IMVT positions and 11 closed out — a net gain of 10 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $49.6M. The largest seller was 683 Capital Management, cutting an estimated $8.81M.
- 24 institutional investors held Immunovant (IMVT) as of Q4 2019, up from 14 in Q3 2019.
- Funds reported $176M of Immunovant stock for Q4 2019, up 382% quarter-over-quarter.
- 21 funds opened new Immunovant positions in Q4 2019 and 11 closed out, a net change of +10 holders.
- The largest Immunovant buyer in Q4 2019 was RTW Investments, an estimated $49.6M added.
- The largest Immunovant seller in Q4 2019 was 683 Capital Management, an estimated $8.81M sold.
Based on aggregated 13F filings for Q4 2019.